Summary of Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2018

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

	Three Months Ended
(In thousands)	September 30,
Medical Indication	2018		2017
Antibiotic	$	4,089	$	3,349
Anti-Psychosis		10,889		14,991
Cardiovascular		21,770		11,306
Central Nervous System		7,197		8,818
Gallstone		2,214		6,564
Gastrointestinal		15,040		14,553
Glaucoma		548		2,668
Migraine		9,737		15,015
Muscle Relaxant		3,179		3,791
Pain Management		4,947		5,761
Respiratory		1,015		1,647
Thyroid Deficiency		53,878		47,214
Urinary		1,552		2,997
Other		14,338		12,696
Contract manufacturing revenue		4,661		3,591
Total	$	155,054	$	154,961

The Company sells its products to customers in various distribution channels.  The table below presents the Company’s net sales to each distribution channel for the three months ended September 30:

(In thousands)	September 30,		September 30,
Customer Distribution Channel	2018		2017
Wholesaler/Distributor	$	116,354	$	120,801
Retail Chain		25,041		18,768
Mail-Order Pharmacy		8,998		11,801
Contract manufacturing revenue		4,661		3,591
Total	$	155,054	$	154,961

Summary of products which accounted for at least 10% of total net sales

	2018		2017
Product 1	35	%	30	%

Summary of customers which accounted for at least 10% of total net sales

	2018		2017
Customer A	29	%	27	%
Customer B	18	%	20	%